A/S = 700,000,000
O/S = 41,736,174 as of March 27, 2009
O/S = 53,239,440 as of May 12, 2009
10-Q May 13, 2009: www.sec.gov/Archives/edgar/data/1190132/000114420409025963/0001144204-09-025963-index.htm
10-K December 31, 2008: http://www.sec.gov/Archives/edgar/data/1190132/000114420409017436/v144703_10k.htm
website: www.chinabiopharma.com.cn
China:
China Biopharma, Inc.
173 Yugu Lu, Zhongtian DaSha 16-L
Hangzhou, 310007 China
www.zhongchaimachinery.com/Contact.asp
USA:
China Biopharma, Inc.
PO Box 6303
Freehold, NJ 07728 USA
Fax: 609-228-4301
Email:
contact.chbo@gmail.com
In January 2009, the Company agreed to reduce a receivable amounting to $1,012,700, owed by Zhejiang Tianyuan Bio-pharmaceutical Co. (“Zhejiang Tianyuan”), a 35% minority interest owner in the subsidiary of ZTBC. In exchange, Zhejiang Tianyuan withdrew its 35% equity interest in ZTBC, and ZTBC reduced approximately $1.05 million in the registered capital. As a result, the Company owns 100% control and ownership in ZTBC, and renames it as Zhejiang Kangchen Biotech Co., Ltd. (“ZKBC”).
China Biopharma, Inc. Issues Corporate Information Update
Hangzhou, China, December 26, 2008: www.chinabiopharma.com.cn/Index_2_Read.asp
The Company had significant operational improvement after the start of corporate operational restructuring last year. For the nine months ended September 30, 2008, it has made approximately $5.4 million in sales, more than thirteen times the sales revenue made in the same period of 2007, which was approximately $0.4 million. It also made approximately $90,000 in net profit from the China operation, comparing to a net loss of approximately $0.35 million in the same period of 2007. The Company believes that the current operation will further improve as it finalizes the operational restructuring.
The Company has signed an agreement with Zhejiang Tianyuan Biopharma Co., Ltd. that the Company will increase its stakes from currently 65% to 100% in the joint venture, Zhejiang Tianyuan Biotech Co., Ltd. (“ZTBC”). ZTBC will become a wholly owned subsidiary of the Company, and will change its name to Zhejiang Kangchen Biotech Co., Ltd. It is waiting for the new business license.
The Company has signed an agreement to acquire 90% of Beijing Tiancheng Xinhai Pharmaceutical Co., Ltd. (“BTXP”), a regional pharmaceutical distribution company. The company now has full operating control in BTXP and is waiting for final governmental approval and new business license.
After completion of recent operational restructuring, the company is looking for future merge and acquisitions. The Company is projecting a 25% sales increase in 2009.
WHAT IS CHINA BIOPHARMA?
CHBO's product development subsidiary was called Zhejiang Tianyuan Biotech Co (ZTBC). (Currently named Zhejiang Kangchen Biotech Co., Ltd.)
CHBO owns 100% of their ZTBC subsidiary. (Zhejiang Kangchen Biotech Co., Ltd.)
CHBO's product distribution subsidiary is called Hainan CITIC Bio-pharmaceutical Development Co (HCBD).
CHBO's ZTBC subsidiary owns 90% of HCBD and the Chinese Center for Disease Control owns the other 10%.
CHBO's HCBD subsidiary is China's biggest third-party vaccine distributor licensed to distribute any vaccines and biopharmaceutical products in China.
CHBO's HCBD distribution network has five regional distribution centers located in Beijing, Shanghai, Guangzhou, Zhengzhou, and Haikou. Each of them have large cool storage facilities.
This cold-chain covers 236 major cities in China. During an outbreak, CHBO is able to deliver vaccines within 24 hours to any part of these cities. CHBO has 268 local Chinese Center for Disease Controls as its major customers.
Takeda, the largest pharmaceutical company in Japan, recognizes the strength of CHBO's distribution network. Takeda is trying to grow their distribution channels in China and just signed a huge distribution deal with CHBO.
TAKEDA
Takeda Products: http://www.takeda.com/products/ethical-drugs/article_896.html
China Biopharma Forms Distribution Agreement with World-Renowned Japanese Pharmaceutical Company Takeda
DASEN® serrapeptase (anti-inflammatory) http://www.chinabiopharma.com.cn/Index_2_Read.asp?PressType=1&ID=61
SPECIALTY PHARMACEUTICAL PRODUCTS
The company has worked with the Japanese pharmaceutical company, Takeda Pharmaceutical Company, Ltd. (“Takeda”), the largest pharmaceutical company in Japan. With global headquarters located in Osaka, Japan, Takeda specializes in the research and development of breakthrough drugs, and has marketing operations throughout U.S., Europe, and Asia. In Japan, Takeda has also built a strong presence in the over-the-counter (OTC) drugs market, in which it holds the second largest domestic share.
After distributing its products for about ten months on a trial basis, both parties are quite happy with the outcomes and decide to continue this relationship and we will commit more resources and increase our capabilities to carry Takeda’s products.
SOONFAST ANTIVIRAL LOTION
China Biopharma Reaches Agreement to Introduce A New Antiviral Drug: http://www.chinabiopharma.com.cn/Index_2_Read.asp?PressType=1&ID=69
China Biopharma has worked with Soonfast Pharmaceutical Science & Technology Co., Ltd. (“Soonfast”) to introduce a new antiviral medicine into the overseas market including the United States and European countries. This all-natural product has been approved in China for external use to treat human papillomavirus (“HPV”) and herpes simplex virus (“HSV”). Tests have shown an inhibitory effect on the growth of HPV and HSV, and the medicine can reduce the infection from HPV and HSV by 90% within only 2-3 days. Experiments have also proved that the herbal can kill all of the HPV types 6/11/16/18 and 33.
China Biopharma Reaches Agreement with a Regional Pharma to Launch New Pharmaceutical Products
http://en.kyxh.com/newEbiz1/EbizPortalFG/portal/html/main.html
Disclaimer:*****The moderator and assistant moderators of this forum are not professional financial/investment consultants and reserve the there right to any opinion and share no responsibilty or liable in there or other persons buying or selling stock investment deciscions and ask that persons or investors be advised in seeking there own individual professional financial counseling or due diligence before buying or selling of any stocks.*****
http://stockcharts.com/h-sc/ui?s=CHBO&p=W&yr=3&mn=0&dy=0&id=p00740380098
http://stockcharts.com/h-sc/ui?s=CHBO&p=D&yr=0&mn=10&dy=0&id=p61179325147
http://stockcharts.com/h-sc/ui?s=CHBO&p=D&yr=0&mn=3&dy=0&id=p17074483516
